.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,362,085

« Back to Dashboard

Claims for Patent: 8,362,085

Title:Method for administering an NMDA receptor antagonist to a subject
Abstract: The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:13/536,525
Patent Claims: 1. A method of treating a patient with a neurological disorder selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain, comprising: administering to said subject once daily a sustained release oral dosage form comprising 22.5 mg to 30 mg of memantine or a pharmaceutically acceptable salt thereof and a component that sustains release of said memantine or salt thereof, wherein said sustained release memantine provides a change in mean plasma concentration of memantine as a function of time (dC/dT) that is: (a) less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0-Tmax of the immediate release form of memantine; and (b) 2.1 ng/ml/hr or less, determined in a time period of 0 to 4 hours; wherein dC/dT is measured in a single-dose human PK study.

2. The method of claim 1, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.

3. The method of claim 1, wherein the sustained release oral dosage form comprises 25 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof.

4. The method of claim 3, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.

5. The method of claim 1, wherein the sustained release oral dosage form comprises 28 mg memantine or a pharmaceutically acceptable salt thereof.

6. The method of claim 5, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.

7. A method of treating a patient with a neurological disorder selected from the group consisting of Alzheimer's disease, dementia, Parkinson's disease, and neuropathic pain, comprising: administering to said subject once daily a sustained release oral dosage form comprising 22.5 mg to 30 mg of memantine or a pharmaceutically acceptable salt thereof and a component that sustains release of said memantine or salt thereof, wherein said sustained release memantine provides a change in mean plasma concentration of memantine as a function of time (dC/dT) that is: (a) less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0 hours and 6 hours of administration of memantine; and (b) 2.1 ng/ml/hr or less, determined in a time period of 0 to 4 hours; wherein dC/dT is measured in a single-dose human PK study.

8. The method of claim 7, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.

9. The method of claim 7, wherein the sustained release oral dosage form comprises 25 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof.

10. The method of claim 9, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.

11. The method of claim 7, wherein the sustained release oral dosage form comprises 28 mg memantine or a pharmaceutically acceptable salt thereof.

12. The method of claim 11, wherein the dC/dT of 2.1 ng/mL/hr or less is determined in a time period of 2 to 4 hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc